About Actin-related protein 2/3 complex subunit 1B
Actin-related protein 2/3 complex subunit 1B (ARPC1B) is a protein
from Homo sapiens identified by UniProt accession
O15143, 372 residues long.
MolForge cross-references it against 0 known binders and
251 disease associations.
Target properties
| Protein name | Actin-related protein 2/3 complex subunit 1B |
| UniProt accession | O15143 |
| Gene | ARPC1B |
| Organism | Homo sapiens |
| Length | 372 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (251)
Diseases linked to this target (Open Targets).
- platelet abnormalities with eosinophilia and immune-mediated inflammatory disease · score 0.74
- combined immunodeficiency · score 0.43
- Combined T and B cell immunodeficiency · score 0.43
- neuroinflammatory disorder · score 0.40
- cutaneous Leishmaniasis · score 0.37
- neurodegenerative disease · score 0.34
- genetic disorder · score 0.19
- endometrial cancer · score 0.18
- alcohol consumption measurement · score 0.18
- breast adenocarcinoma · score 0.18
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O15143-F1 | alphafold | PREDICTED | 92.42 | — |
Amino-acid sequence (372 residues)
MAYHSFLVEP ISCHAWNKDR TQIAICPNNH EVHIYEKSGA KWTKVHELKE HNGQVTGIDW APESNRIVTC GTDRNAYVWT LKGRTWKPTL VILRINRAAR CVRWAPNENK FAVGSGSRVI SICYFEQEND WWVCKHIKKP IRSTVLSLDW HPNNVLLAAG SCDFKCRIFS AYIKEVEERP APTPWGSKMP FGELMFESSS SCGWVHGVCF SASGSRVAWV SHDSTVCLAD ADKKMAVATL ASETLPLLAL TFITDNSLVA AGHDCFPVLF TYDAAAGMLS FGGRLDVPKQ SSQRGLTARE RFQNLDKKAS SEGGTAAGAG LDSLHKNSVS QISVLSGGKA KCSQFCTTGM DGGMSIWDVK SLESALKDLK IK
Explore Actin-related protein 2/3 complex subunit 1B with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets